Silvio Inzucchi, MD

Silvio Inzucchi, MD

Professor of Medicine (Endocrinology)
Clinical Director, Section of Endocrinology
Director, Yale Diabetes Center
Director, Endocrinology & Metabolism Fellowship
New Haven, Connecticut

Related Videos

What was the physiological, safety, and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? Video

What was the physiological, safety, and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation?

What was the physiological, safety, and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation?

How do we assess to what degree PPG is playing a role in failing to achieve goal-directed HA1c levels? How do we use FPG and PPG to determine the need for agents for PPG control? Video

How do we assess to what degree PPG is playing a role in failing to achieve goal-directed HA1c levels? How do we use FPG and PPG to determine the need for agents for PPG control?

From a practical perspective, how do we assess to what degree PPG is playing a role in failing to achieve goal-directed HA1c levels? How do we use FPG and PPG levels to determine the need for agents useful for PPG control?

What is the importance of PPG and glucose excursions as a management metric and what are the implications for selecting a specific GLP-1 RA with a specific PK/PD profile? Video

What is the importance of PPG and glucose excursions as a management metric and what are the implications for selecting a specific GLP-1 RA with a specific PK/PD profile?

What is the importance of postprandial hyperglycemia (PPG) and glucose excursions as a management metric and what are the implications for selecting a specific GLP-1 RA with a specific PK/PD profile?

How would you deploy the fixed ratio combination agents in a 58-year old obese male patient who was not meeting HA1c target goals on metformin alone, or a second oral agent? Video

How would you deploy the fixed ratio combination agents in a 58-year old obese male patient who was not meeting HA1c target goals on metformin alone, or a second oral agent?

How would deploy the fixed ratio combination agents in a 58-year old obese male patient who was not meeting HA1c target goals on metformin alone, or a second oral agent?

Where might the fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA fit into the ADA and AACE guidelines and how do your see their use in the sequencing algorithm for T2D? Video

Where might the fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA fit into the ADA and AACE guidelines and how do your see their use in the sequencing algorithm for T2D?

Where might the fixed ratio, combination regimens consisting of a long-acting insulin and GLP-1 RA fit into the ADA and AACE guidelines and how do your see their use in the sequencing algorithm for T2D?